Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cellectar Biosciences, Inc., a Delaware corporation, filed this Current Report on Form 8-K on July 27, 2018. The filing discloses the pricing of an underwritten public offering of equity securities.
Key Financial Metrics and Capital Structure
The filing details a capital raise with the following terms:
- Gross Proceeds: $14.4 million (before underwriting discounts and expenses).
- Common Stock: 815,000 shares offered.
- Series C Convertible Preferred Stock: 1,114 shares offered, convertible into 2,785,000 shares of Common Stock.
- Warrants: Warrants to purchase 3,600,000 shares of Common Stock included in the offering.
- Offering Price: $4.00 per share of Common Stock plus one Warrant; $10,000 per share of Series C Preferred Stock plus associated Warrants.
- Warrant Terms: Exercise price of $4.00 per share; exercisable for five years.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Over-Allotment
In addition to the primary offering, the Company granted underwriters a 45-day option to purchase up to 540,000 additional shares of Common Stock and Warrants to purchase up to 540,000 shares of Common Stock. The offering is expected to close on or about July 31, 2018, subject to customary closing conditions.
Management Commentary and Risks
The offering is being conducted pursuant to a Registration Statement on Form S-1 (File No. 333-225675) initially filed on June 15, 2018, and a Rule 462(b) registration statement (File No. 333-226374). Ladenburg Thalmann & Co. Inc. served as the sole book-running manager, with CIM Securities, LLC acting as co-manager. The filing does not contain specific management commentary on operational risks or contingencies beyond the standard closing conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected July 31, 2018).
- Confirm the net proceeds after deducting underwriting discounts and offering expenses.
- Monitor whether the underwriters exercise the 45-day option for the additional 540,000 shares.
- Review the full Form S-1 (File No. 333-225675) for detailed risk factors and use of proceeds.